CRLF2 (Verekitug Biosimilar) Recombinant Monoclonal Antibody

說明書

貨號：

CSB-RA005983MB1HU
規格：
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

Uniprot No.：

Q9HC73
基因名：

CRLF2
別名：

CRL 2 antibody; CRL2 antibody; CRLF 2 antibody; Crlf2 antibody; CRLF2_HUMAN antibody; CRLF2Y antibody; Cytokine receptor CRL2 precusor antibody; Cytokine receptor like 2 antibody; Cytokine receptor like factor 2 antibody; Cytokine receptor like factor 2 precursor antibody; Cytokine receptor-like 2 antibody; Cytokine receptor-like factor 2 antibody; IL XR antibody; IL-XR antibody; ILXR antibody; Thymic stromal derived lymphopoietin receptor antibody; Thymic stromal lymphopoietin protein receptor antibody; Thymic stromal lymphopoietin receptor antibody; TSLP receptor antibody; TSLPR antibody
反應種屬：

Human, Macaca fascicularis
免疫原：

Recombinant Human CRLF2 protein
免疫原種屬：

Homo sapiens (Human)
標記方式：

Non-conjugated
克隆類型：

Monoclonal
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.177
產品提供形式：

Liquid
應用說明：

Validation Status
Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
Guaranteed Quality
① Antibody purity?> 95% tested by SDS-PAGE.
② Endotoxin level < 0.1EU/ug tested by LAL method.
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

In stock
用途：

It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產品評價

靶點詳情

功能：

Receptor for thymic stromal lymphopoietin (TSLP). Forms a functional complex with TSLP and IL7R which is capable of stimulating cell proliferation through activation of STAT3 and STAT5. Also activates JAK2. Implicated in the development of the hematopoietic system.
基因功能參考文獻：
1. Family-based whole genome analysis of a family with hereditary pulmonary alveolar proteinosis revealed a homozygous deletion that disrupts CSF2RA, CRLF2, and IL3RA gene in the pseudoautosomal region of the X chromosome in the affected child and one of asymptomatic siblings. PMID: 28233860
2. TSLP expression on the basophil membrane of patients with severe asthma was not significantly different from healthy controls. PMID: 29402810
3. high CRLF2 expression works with the IKZF1 deletion to drive oncogenesis of acute lymphoblastic leukemia PMID: 27391346
4. this study shows that CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia PMID: 27449287
5. data suggest that this high frequency of genetic aberrations in the context of a high CRLF2 expression could contribute to the high risk of relapse in P2RY8/CRLF2- and IGH/CRLF2-positive acute lymphoblastic leukemia. PMID: 28371317
6. CRLF2 overexpression is associated with childhood B-cell acute lymphoblastic leukemia. PMID: 27637012
7. CRLF2 gene rearrangement is associated with acute lymphoblastic leukemia. PMID: 28033648
8. TSLPR levels were found to be significantly higher in asthmatic than in nonasthmatic children. TSLPR expression in non-allergic asthmatic and allergic asthmatic groups was found to be significantly higher than in non-allergic nonasthmatic group PMID: 26999524
9. In adult B-cell acute lymphoblastic leukemia without recurrent fusion genes , high CRLF2 expression is associated with distinct clinico-biological features and an unfavourable prognosis PMID: 26754556
10. CD4+ T cells from atopic dermatitis patients directly interacted with TSLP to produce a higher amount of IL-4 than those from normal subjects, and this action was attenuated with anti-TSLPR antibody PMID: 26288354
11. The levels of mRNA for TSLP and TSLPR were significantly elevated in parotid gland tissues from the KD group as compared to the control group. PMID: 25676453
12. Differences exist in the genetic profiles of Down syndrome-associated acute lymphoblastic leukemia patients in Japan and in Western countries, and that P2RY8-CRLF2 and EBF1 deletions may cooperate in leukemogenesis in a subset of Japanese DS-ALL patients. PMID: 25044358
13. CRLF2 overexpression (OE) was detected in 30 (18%) of 167 patients, the P2RY8-CRLF2 fusion was identified in only 3 (1.8%) of 167 patients, all of which demonstrated CRLF2 OE. PMID: 24935070
14. we report noncysteine in-frame mutations in IL7R and CRLF2 located in a region of the transmembrane domain closer to the cytosolic domain in acute lymphoblastic leukemias PMID: 24787007
15. The TSLPR in blood plateltes promotes platelet activation via activating the PI3K/AKT pathway. PMID: 24356513
16. both IKZF1 deletions and IGH@-CRLF2 are associated with an increased risk of treatment failure in adult acute lymphoblastic leukemia PMID: 24018820
17. Data indicate that CD66c is frequently expressed in CRLF2-positive as well as hypodiploid cases. PMID: 24231528
18. Higher cumulative incidence of relapse was found for BCR-ABL1-like and IKZF1-deleted, but not CRLF2-high, cases relative to remaining BCP-ALL cases. PMID: 23974192
19. IKZF1 deletions and CRLF2-high expression predicted poor outcomes in patients with HR-ALL but not in patients with SR-ALL in our Japanese cohort PMID: 23804397
20. Results show no clinical or laboratory difference between those with high and low crlf2 expression PMID: 23145900
21. P2RY8-CRLF2-positive clones do not have the necessary proliferative or selective advantage to evolve into a disease-relevant relapse clone. PMID: 23091296
22. Neither CRLF2 nor JAK2 were predictors for worse prognosis in children with Down's syndrome and acute lymphoblastic leukemia. PMID: 22441210
23. Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia. PMID: 22484421
24. CRLF2-overexpressing B-cell acute lymphoblastic leukemias have a gain-of-function CRLF2 F232C mutation or activating mutations in JAK2. PMID: 22915648
25. CRLF2-deregulation and IGH locus translocations represent distinct subtypes of adolescent and adult acute lymphoblastic leukemia. PMID: 22851563
26. This review sums up diverse mechanisms that mediate TSLP/TSLP receptor-signalling network in chronic airway diseases. PMID: 22168549
27. CRLF2 overexpression is associated with acute lymphoblastic leukemia. PMID: 22297722
28. High CRLF2 expression is associated with a very poor outcome in high-risk, but not standard-risk, acute lymphoblastic leukemia. PMID: 22368272
29. Data indicate that overexpression of CRLF2 was not observed in adult patients with Ph-positive or T-ALL but was limited to B-ALL patients with a normal diagnostic karyotype. PMID: 21457190
30. review highlights the current knowledge of the incidence, prognostic significance, and biology of CRLF2-overexpressing ALL and future directions for development of targeted therapies PMID: 22150304
31. TSLPR expression was significantly higher in the inflammatory infiltrate and in the epithelial cells of chronic rhinosinusitis with or without nasal polyps PMID: 21978707
32. Integrated genomic profiling has identified potential therapeutic targets in acute lymphoblastic leukemia, including aberrant cytokine receptor signaling mediated by rearrangements and mutation of CRLF2 PMID: 21169835
33. Deregulated expression of CRLF2 (CRLF2-d) arises via its juxtaposition to the IGH@ enhancer or P2RY8 promoter. Among 865 BCP-ALL children treated on MRC ALL97, 52 (6%) had CRLF2-d, but it was more prevalent among Down syndrome patients (54%). PMID: 21106984
34. increased CRLF2 expression associates with JAK2 mutation, a combination that transforms hematopoietic cells, suggesting that mutant JAK2 and CRLF2 may cooperate to contribute to B-progenitor acute lymphoblastic leukemia formation [review] PMID: 20807819
35. The genotype and allele frequencies of the g.33G>C and g.19646A>G of the TSLPR gene were significantly associated in the atopic asthma patients rather than in the non-atopic asthma patients PMID: 20663412
36. Studies indicate that of 19 total CRLF2 breakpoints, 7 are directly at CpGs and breakpoints are much closer to CpGs than expected by random chance. PMID: 20847213
37. Study reports an extremely high incidence of relapse (71% +/- 19%) in non-high-risk precursor B-cell acute lymphoblastic leukemia patients with P2RY8-CRLF2 rearrangement. PMID: 20378752
38. Activation of CRLF2 expression, mutation of of JAK1 or JAK2, and alterations of IKZF1 cooperate to promote B-cell leukemogenesis. PMID: 20139093
39. The hymic stromal lymphopoietin receptor is involved in the pathogenesis of allergic asthma through the activation of human airway smooth muscle cells by t hymic stromal lymphopoietin PMID: 20483734
40. human TSLP receptor requires the function of JAK1 and JAK2 for STAT activation PMID: 20128689
41. Activating mutation in the TSLPR gene in B-cell precursor lymphoblastic leukemia; results indicate that TSLPR activation may occur independently of a JAK2R683 mutation and that TSLPR can also be the site of a point mutation PMID: 19907440
42. Our data indicate that epithelial cells express TSLPR and that TSLP induces bronchial epithelial cell proliferation and increases injury repair through IL-13 production. PMID: 20236697
43. Induced homodimerization of receptor chimeras containing the transmembrane and cytoplasmic domains of both human and mouse TSLP receptors is not sufficient for driving cell proliferation. PMID: 20096461
44. Results implicate CRLF2 as an important factor in precursor B-cell acute lymphoblastic leukemia with diagnostic, prognostic, and therapeutic implications. PMID: 20018760
45. Results suggest that the majority of DS children with ALL may benefit from therapy blocking the CRLF2/JAK2 pathways. PMID: 19965641
46. Expression of TSLP receptor was upregulated on atopic DCs primed with H22-Fel d 1 through a pathway regulated by FcgammaRI-associated signaling components. PMID: 20109752
47. The presence of TSLP receptors is unexpectedly demonstrated on activated human CD4-positive T cells. PMID: 17513717
48. A causal role of CRLF2 overexpression in lymphoid transformation. PMID: 19641190
49. report a recurring interstitial deletion of the pseudoautosomal region 1 of chromosomes X and Y in B-progenitor acute lymphoblastic leukemia that juxtaposes the first, noncoding exon of P2RY8 with the coding region of CRLF2. PMID: 19838194
顯示更多

收起更多
亞細胞定位：

[Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.
蛋白家族：

Type I cytokine receptor family, Type 5 subfamily
組織特異性：

Expressed in heart, skeletal muscle, kidney and adult and fetal liver. Primarily expressed in dendrites and monocytes. Weakly expressed in T-cells.
數據庫鏈接：

HGNC: 14281

OMIM: 300357

KEGG: hsa:64109

STRING: 9606.ENSP00000370979

UniGene: Hs.287729

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human